Party safer: Tips for a safe summer party season
With summer festival season in full swing and vacations underway, it's party time for thousands of people across Ottawa.
Ottawa Public Health has launched a new online tool to help people party safely, especially when alcohol or drugs are involved.
'We know that alcohol and drugs are a part of the festivities and celebration often, too,' Megan Francoeur, with Ottawa Public Health, told CTV Morning Live. 'Just making sure that we're not mixing substances, starting low, going slow, looking out for each other, getting naloxone, making sure that we know how to respond to overdose and intoxication.'
PartySafer.ca includes free online trainings, printable materials, social media tools, and community resources for event goers and event organizers.
'There's resources for event staff and volunteers, free trainings that take 15 minutes with some really practical tips and also resources for parents and guardians to talk about substance use with your teens and also festivalgoers and school students,' said Francoeur.
The site has details on commonly used substances like alcohol, cannabis, opioids, and tobacco, along with information on harm reduction and naloxone use, including where to get naloxone kits.
Naloxone
A naloxone kit is shown in this undated image. (Peter Szperling/CTV News Ottawa)
The site also has information on mental health and addictions resources, bystander intervention and violence prevention, and safe sex.
'People are out more and we've been out at special events recently and it's been so nice to see the response from thousands of people coming up, saying they're happy to be doing this type of training and we love to see it when somebody walks by our tent and goes, 'I already have a (naloxone) kit,'' Francoeur said.
The free trainings require an Olearn account, which is free to set up, but other resources including tips, information, and links to service providers are freely accessible on the PartySafer.ca website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
29 minutes ago
- National Post
Orpyx Launches Sensory Insole Program to Combat >$80B Annual Cost of Diabetic Foot Complications
Article content CALGARY, Alberta — Orpyx® Medical Technologies Inc., a leader in sensor-based remote monitoring, today announced the launch of its next-generation sensory insole program, a proactive, scalable solution to prevent the most costly and preventable consequences of diabetes. In the US alone, one in every three diabetes-related healthcare dollars goes toward managing foot-related complications, representing over $80 billion annually (Armstrong et al., Journal of Foot and Ankle Research, 2020). Article content Article content The Orpyx® Sensory Insoles are embedded with proprietary sensors that continuously track plantar pressure, foot temperature, step count, and wear time — physiological indicators that signal early deterioration in foot health. Designed for effortless patient use, the insoles function for up to six months without charging and sync with an intuitive mobile app and home hub that uploads data directly and securely to the Orpyx cloud. 'This new platform combines durable wearable technology and behavioral support to enable healthcare providers to intervene early before complications escalate,' said Dr. Breanne Everett, CEO and founder of Orpyx. 'Our goal is to help people stay healthy, avoid hospitalizations, and maintain control over their health. This launch is a key milestone as we scale across government and commercial value-based care markets, supporting high-risk individuals while delivering meaningful value for healthcare systems and payers who are under increasing pressure to improve outcomes while managing costs more effectively.' Article content Each program participant is paired with a dedicated Orpyx nurse who delivers personalized coaching, adherence support, and wellness checks, bridging the gap between medical appointments to help ensure continuity of care. This model supports both better outcomes and operational scalability for chronic disease management programs. Article content The Orpyx technology is clinically validated and economically proven in multiple peer-reviewed publications. In a randomized controlled trial, individuals who wore an earlier-generation Orpyx insoles for 4.5+ hours daily experienced an 86% reduction in foot re-ulceration (Abbott et al., Lancet Digital Health, 2019). A separate cost-effectiveness study reported an 84% reduction in ulcer occurrence within three months, along with a 70% decrease in total projected costs (Najafi et al., Wound Care Management, 2018). Article content 'This product launch represents a significant advancement in orthotic technology. Clinicians can now medically monitor or intervene with patients living with chronic foot conditions that put them at risk for serious complications', said Dr. Daniel Ferreras, DPM, FAPWCA, AAWC. 'By combining clinically validated technology with personalized support, we're providing patients the tools they need to stay healthier, avoid hospitalization, and maintain their independence.' Article content Foot complications are a leading cause of diabetes-related hospitalization, amputation, and long-term disability, which are largely preventable with early detection and intervention. The Orpyx Sensory Insole program is built to support value-based care models for health systems, ACOs, and payers focused on managing this high-risk, high-cost population living with diabetes. Article content About Orpyx Medical Technologies Inc. Article content Orpyx® is a health technology company transforming the prevention of diabetic foot complications through its patented sensor-enabled smart insole system and integrated remote care program. Built to detect early warning signs and prompt timely intervention, the Orpyx solution helps improve adherence, reduce total costs, and preserve mobility and quality of life. The company partners with VA Medical Centers, health systems, and payers across North America to deliver clinically validated outcomes and cost savings at scale. Article content Article content Article content Contacts Article content Media Inquiries: Article content Article content Karen Smith Article content Article content
National Post
29 minutes ago
- National Post
ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation
Article content Article content TORONTO — ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from both the U.S. Food and Drug Administration (FDA) and Health Canada to initiate a Phase I clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of its lead candidate, PQ203. The FDA has also granted PQ203 Fast Track designation for patients with triple negative breast cancer, recognizing the therapy's potential to address a serious unmet medical need. Article content The upcoming Phase I trial, which will be conducted in both the United States and Canada, will use an accelerated titration design to more efficiently identify the optimal dosing regimen while quickly arriving at therapeutic dose levels. Article content 'This is a major step forward for ProteinQure and for the field of rationally designed peptide therapeutics,' Article content said Dave Garman, VP Translation and Development at ProteinQure. Article content 'The Fast Track designation reflects the FDA's recognition of the promise PQ203 holds for cancer patients, and we are thrilled to move swiftly into the clinic across North America.' Article content PQ203 is a first-in-class therapeutic developed using ProteinQure's proprietary platform that integrates physics-based modeling with generative machine learning. The company believes PQ203 could unlock new frontiers in oncology by combining high specificity with novel mechanisms of action. Article content The Phase I study is expected to begin at Princess Margaret Cancer Centre in Toronto, with expansion to U.S. clinical sites later this year. Article content About PQ203 Article content PQ203 is the company's first internally owned AI designed peptide therapeutic entering the clinic. PQ203 is a novel Peptide Drug Conjugate composed of a peptide targeting the Sortilin receptor conjugated to the cytotoxic agent monomethyl auristatin E. The Sortilin receptor is expressed in a high percentage of diseased tissue from Triple Negative Breast Cancer (TNBC) patients and as such represents a novel target for this challenging sub-type of breast cancer. ProteinQure has generated data that PQ203 exhibits potent efficacy in multiple patient-derived xenograft (PDX) models including those resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Article content Article content Article content
CBC
30 minutes ago
- CBC
Naloxone kits, defibrillators to be required in all B.C. high schools by December
Social Sharing Naloxone kits and defibrillators will be required in all secondary schools in British Columbia by the end of the year. The change is part of an updated healthy emergencies policy from the province that will also see Grade 10 students trained in first aid during gym class, beginning in September. Students will be taught CPR and how to use automated external defibrillators (AEDs), but schools will not be required to provide naloxone training, according to the Ministry of Education and Childcare. Tobias Zhang is happy about the changes. The Grade 12 student at Point Grey Secondary in Vancouver has been an advocate for AEDs in schools since his friend died after going into cardiac arrest at school three years ago. "There was no AED to help save my friend when he needed one," he said. A year after his friend died, Zhang founded a group to fundraise for the installation of an AED at his school. WATCH | Zhang calls for defibrillators in schools following friend's death: Student pushes for defibrillator access in Vancouver schools 8 months ago A Point Grey Secondary School student, whose friend died in 2022 during basketball practice, says having a defibrillator on site could have made all the difference. Tobias Zhang is now pushing to get the lifesaving technology into schools — something staff say they're working on. He says it took another year of meeting with school board chairs for the Vancouver School Board to accept his group's donation of about $14,000. In May, the board earmarked $250,000 of its own budget to purchase and install AEDs in all the district's facilities by September. More training needed Leslie McBain, co-founder of Moms Stop the Harm, commends the decision to stock schools with naloxone kits. "If someone does lose consciousness or go down from an overdose of toxic drugs, their life could probably be saved with naloxone," she said. However, she says she's disappointed that schools won't be required to train students on how to use the life-saving kits. She says that while giving nasal naloxone isn't complicated, training is essential because every second counts when someone is experiencing an overdose. "Until we get a safe supply of drugs in its many variations, those toxic drugs are going to be out there and overdose is a potential outcome," she said. More than 16,000 people have died from the toxic drugs crisis since B.C. declared it a public health emergency in 2016, over 200 of them under the age of 19. McBain says she thinks naloxone training could also make students more alert to the risks of using substances and serve as an educational intervention to prevent overdoses. Abbotsford going a step further In the Abbotsford School District, students will get that extra education. They will be trained on how to administer naloxone, as well as perform CPR and use an AED, according to superintendent Nathan Ngieng. Ngieng says he believes naloxone kits are an important safety measure. "We've seen incidents of overdose death in Abbotsford here, so equipping young people to respond in those emergency situations is really important," he said. He says Abbotsford schools have already had AEDs for close to 10 years and one has already been used to save a student's life. "Because we've had a real-life application, it really hits home for us in terms of understanding how this simple act of including this learning standard could save the life of a student or individual," he said.
